Dose-toxicity models in oncology

Bibliography

• E8 harmonised tripartite guideline. General considerations for clinical trials. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. Available from: http://www.ich.org/LOB/media/MEDIA484.pdf [Last accessed 5 November 2010]
   Google Scholar
• S6 preclinical safety evaluation of biotechnology-derived pharmaceuticals. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. Available from: http://www.ich.org/LOB/media/MEDIA503.pdf [Last accessed 5 November 2010]
   Google Scholar
• S7A safety pharmacology studies for human pharmaceuticals. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. Available from: http://www.ich.org/LOB/media/MEDIA504.pdf [Last accessed 5 November 2010]
   Google Scholar
• M3 (R2) Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. Available from: http://www.ich.org/LOB/media/MEDIA5544.pdf [Last accessed 5 November 2010]
   Google Scholar
• O'Quigley J, Zohar S. Experimental designs for phase I and phase I/II dose-finding studies. Br J Cancer 2006;94:609-13
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-15
   PubMed Web of Science ®Google Scholar
• Laska DA, Houchins JO, Pratt SE, Characterization and application of a vinblastine-selected CACO-2 cell line for evaluation of p-glycoprotein. In Vitro Cell Dev Biol Anim 2002;38:401-10
   PubMed Web of Science ®Google Scholar
• Yuan R, Parmelee T, Balian JD, In vitro metabolic interaction studies: experience of the Food and Drug Administration. Clin PharmacolTher 1999;66:9-15
   Google Scholar
• Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003;2:566-80
   PubMed Web of Science ®Google Scholar
• Johnson JI, Decker S, Zaharevitz D, Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-31
   PubMed Web of Science ®Google Scholar
• Mandrekar SJ, Cui Y, Sargent DJ. An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Stat Med 2007;26:2317-30
   PubMed Web of Science ®Google Scholar
• Suntharalingam G, Perry MR, Ward S, Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355:1018-28
   PubMed Web of Science ®Google Scholar
• Kinders R, Parchment RE, Ji J, Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv 2007;7:325-34
   PubMed Web of Science ®Google Scholar
• The Lancet. Phase 0 trials: a platform for drug development? Lancet 2009;374:176
   Web of Science ®Google Scholar
• Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies. U.S. Department of Health and Human Services and Center for Drug Evaluation and Research, Food and Drug Administration, Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078933.pdf [Last accessed 5 November 2010]
   Google Scholar
• Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res 2010;16:1726-36
   Google Scholar
• Rosenberger WF, Haines LM. Competing designs for phase I clinical trials: a review. Stat Med 2002;21:2757-70
   PubMed Web of Science ®Google Scholar
• Le TC, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708-20
   PubMed Web of Science ®Google Scholar
• Postel-Vinay S, Arkenau HT, Olmos D, Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer 2009;100:1373-8
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Turner J. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 1991;9:115-22
   PubMed Web of Science ®Google Scholar
• Rogatko A, Schoeneck D, Jonas W, Translation of innovative designs into phase I trials. J Clin Oncol 2007;25:4982-6
   PubMed Web of Science ®Google Scholar
• O'Quigley J, Chevret S. Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Stat Med 1991;10:1647-64
   PubMed Web of Science ®Google Scholar
• Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989;45:925-37
   PubMed Web of Science ®Google Scholar
• Kwak EL, Camidge DR, Clark J, Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 2009;27: abstract 3509
   Web of Science ®Google Scholar
• Flaherty K, Puzanov I, Sosman JKK, Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009;27: abstract 9000
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Beal SL, Sambol NC. Study designs for dose-ranging. Clin Pharmacol Ther 1989;46:63-77
   PubMed Web of Science ®Google Scholar
• Sheiner LB. Implications of an alternative approach to dose-response trials. J Acquir Immune Defic Syndr 1990;3(Suppl 2):S20-6
   PubMedGoogle Scholar
• Simon R, Freidlin B, Rubinstein L, Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47
   PubMed Web of Science ®Google Scholar
• Dancey J, Freidlin B, Rubinstein L. Accelerated titration designs. In: Statistical methods for dose-finding experiments. Wiley, Chichester; 2006. p. 91-114
   Google Scholar
• Mross K, Stefanic M, Gmehling D, Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16:311-19
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Burris HA III, Jones S, Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007;25:1082-8
   PubMed Web of Science ®Google Scholar
• Horstmann E, McCabe MS, Grochow L, Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005;352:895-904
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Benjamin RS. Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med 2005;352:930-2
   PubMed Web of Science ®Google Scholar
• Decoster G, Stein G, Holdener EE. Responses and toxic deaths in phase I clinical trials. Ann Oncol 1990;1:175-81
   PubMed Web of Science ®Google Scholar
• Babb JS, Rogatko A. Bayesian methods for cancer phase I clinical trials. In: Advances in Clinical Trial Biostatistics. Marcel Dekker, New York; 2004
   Google Scholar
• Collins JM, Grieshaber CK, Chabner BA. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 1990;82:1321-6
   PubMed Web of Science ®Google Scholar
• Collins JM, Zaharko DS, Dedrick RL, Chabner BA. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 1986;70:73-80
   PubMedGoogle Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95
   PubMed Web of Science ®Google Scholar
• Goulart BH, Clark JW, Pien HH, Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 2007;13:6719-26
   PubMed Web of Science ®Google Scholar
• Collins JM. Phase 0 clinical studies in oncology. Clin Pharmacol Ther 2009;85:204-7
   PubMed Web of Science ®Google Scholar
• Bayes T. An essay towards solving a problem in the doctrine of chances. Philos Trans R Soc Lond 1763;53:370-418
   Google Scholar
• Berry DA. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis. Clin.Trials 2005;2:295-300
   PubMed Web of Science ®Google Scholar
• Berry DA, Cronin KA, Plevritis SK, Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92
   PubMed Web of Science ®Google Scholar
• Cheng JD, Babb JS, Langer C, Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. J Clin Oncol 2004;22:602-9
   PubMed Web of Science ®Google Scholar
• Gallo JM, Laub PB, Rowinsky EK, Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol 2000;18:2459-67
   PubMed Web of Science ®Google Scholar
• Maki RG, Wathen JK, Patel SR, Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007;25:2755-63
   PubMed Web of Science ®Google Scholar
• Saunders M, Dische S, Barrett A, Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997;350:161-5
   PubMed Web of Science ®Google Scholar
• Dische S, Saunders M, Barrett A, A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;44:123-36
   PubMed Web of Science ®Google Scholar
• Saunders M, Dische S, Barrett A, Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999;52:137-48
   PubMed Web of Science ®Google Scholar
• Adamina M, Tomlinson G, Guller U. Bayesian statistics in oncology: a guide for the clinical investigator. Cancer 2009;115:5371-81
   PubMed Web of Science ®Google Scholar
• Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health care evaluation. Wiley, New York; 2004
   Google Scholar
• Kadane JB. Prime time for Bayes. Control Clin Trials 1995;16:313-18
   PubMedGoogle Scholar
• Goodman SN. Toward evidence-based medical statistics. 1: the P value fallacy. Ann Intern Med 1999;130:995-1004
   PubMed Web of Science ®Google Scholar
• Goodman SN. Introduction to Bayesian methods I: measuring the strength of evidence. Clin Trials 2005;2:282-90
   PubMed Web of Science ®Google Scholar
• Sung L, Hayden J, Greenberg ML, Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. J Clin Epidemiol 2005;58:261-8
   PubMed Web of Science ®Google Scholar
• Austin PC, Brunner LJ, Hux JE. Bayeswatch: an overview of Bayesian statistics. J Eval Clin Pract 2002;8:277-86
   PubMed Web of Science ®Google Scholar
• Huang X, Biswas S, Oki Y, A parallel phase I/II clinical trial design for combination therapies. Biometrics 2007;63:429-36
   PubMed Web of Science ®Google Scholar
• Yin G, Li Y, Ji Y. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios. Biometrics 2006;62:777-84
   PubMed Web of Science ®Google Scholar
• Vey N, Kantarjian H, Beran M, Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. Invest New Drugs 1999;17:89-95
   PubMed Web of Science ®Google Scholar
• Rogatko A, Babb JS, Tighiouart M, New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res 2005;11:5342-6
   PubMed Web of Science ®Google Scholar
• Whitehead J, Zhou Y, Stevens J, Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit. Stat Med 2006;25:37-53
   PubMed Web of Science ®Google Scholar
• Loke YC, Tan SB, Cai Y, Machin D. A Bayesian dose finding design for dual endpoint phase I trials. Stat Med 2006;25:3-22
   PubMed Web of Science ®Google Scholar
• Hamberg P, Ratain MJ, Lesaffre E, Verweij J. Dose-escalation models for combination phase I trials in oncology. Eur J Cancer 2010;46:2870-8
   PubMed Web of Science ®Google Scholar
• DeMets DL. Practical aspects in data monitoring: a brief review. Stat Med 1987;6:753-60
   PubMed Web of Science ®Google Scholar
• O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990;46:33-48
   PubMed Web of Science ®Google Scholar
• O'Quigley J. Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer. Biometrics 1992;48:853-62
   PubMed Web of Science ®Google Scholar
• O'Quigley J, Shen LZ. Continual reassessment method: a likelihood approach. Biometrics 1996;52:673-84
   PubMed Web of Science ®Google Scholar
• Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995;14:1149-61
   PubMed Web of Science ®Google Scholar
• O'Quigley J, Paoletti X. Continual reassessment method for ordered groups. Biometrics 2003;59:430-40
   PubMed Web of Science ®Google Scholar
• Faries D. Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat 1994;4:147-64
   PubMedGoogle Scholar
• Potter DM. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer. Stat Med 2002;21:1805-23
   PubMed Web of Science ®Google Scholar
• Siu LL, Rowinsky EK, Hammond LA, A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. Clin Cancer Res 2002;8:2157-66
   PubMed Web of Science ®Google Scholar
• Tighiouart M, Rogatko A, Babb JS. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Stat Med 2005;24:2183-96
   PubMed Web of Science ®Google Scholar
• Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 1998;17:1103-20
   PubMed Web of Science ®Google Scholar
• Babb JS, Rogatko A. Patient specific dosing in a cancer phase I clinical trial. Stat Med 2001;20:2079-90
   PubMed Web of Science ®Google Scholar
• Normolle D, Lawrence T. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. J Clin Oncol 2006;24:4426-33
   PubMed Web of Science ®Google Scholar
• Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 2000;56:1177-82
   PubMed Web of Science ®Google Scholar
• Muler JH, McGinn CJ, Normolle D, Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol 2004;22:238-43
   PubMed Web of Science ®Google Scholar
• Masson E, Zamboni WC. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Clin Pharmacokinet 1997;32:324-43
   PubMed Web of Science ®Google Scholar
• Freyer G, Ligneau B, Tranchand B, Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice. Cancer Treat Rev 1997;23:153-69
   PubMed Web of Science ®Google Scholar
• Calvert AH, Newell DR, Gumbrell LA, Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56
   PubMed Web of Science ®Google Scholar
• Chatelut E, Canal P, Brunner V, Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995;87:573-80
   PubMed Web of Science ®Google Scholar
• Mercier C, Ciccolini J, Pourroy B, Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities. Ther Drug Monit 2006;28:212-18
   PubMed Web of Science ®Google Scholar
• Rousseau A, Marquet P, Debord J, Adaptive control methods for the dose individualisation of anticancer agents. Clin Pharmacokinet 2000;38:315-53
   PubMed Web of Science ®Google Scholar
• Johansen MJ, Madden T, Mehra RC, Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer. J Clin Oncol 1997;15:1481-91
   PubMed Web of Science ®Google Scholar
• Salas S, Mercier C, Ciccolini J, Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma. Ther Drug Monit 2006;28:532-9
   PubMed Web of Science ®Google Scholar
• Jelliffe RW, Schumitzky A, Bayard D, Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new ‘multiple model’ dosage design, bayesian feedback and individualised target goals. Clin Pharmacokinet 1998;34:57-77
   PubMed Web of Science ®Google Scholar
• Perdaems N, Bachaud JM, Rouzaud P, Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule. Eur J Clin Pharmacol 1998;54:677-83
   PubMed Web of Science ®Google Scholar
• Rodman JH, Furman WL, Sunderland M, Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients. J Clin Oncol 1993;11:287-93
   PubMed Web of Science ®Google Scholar
• Rodman JH, Sunderland M, Kavanagh RL, Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients. Cancer Res. 1990;50:4267-71
   PubMed Web of Science ®Google Scholar
• Wong M, Balleine RL, Blair EY, Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol 2006;24:2448-55
   PubMed Web of Science ®Google Scholar
• Gauvin A, Pinguet F, Culine S, Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res 2000;6:2690-5
   PubMed Web of Science ®Google Scholar
• Tranchand B, Amsellem C, Chatelut E, A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 1999;43:316-22
   PubMed Web of Science ®Google Scholar
• Sonnichsen DS, Ribeiro RC, Luo X, Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors. Clin Pharmacol Ther 1995;58:99-107
   PubMed Web of Science ®Google Scholar
• Rousseau A, Sabot C, Delepine N, Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma. Clin Pharmacokinet 2002;41:1095-104
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV, Rodman JH, Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338:499-505
   PubMed Web of Science ®Google Scholar
• Pignon T, Lacarelle B, Duffaud F, Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 1994;33:420-4
   PubMed Web of Science ®Google Scholar
• Pignon T, Lacarelle B, Duffaud F, Dosage adjustment of high-dose methotrexate using Bayesian estimation: a comparative study of two different concentrations at the end of 8-h infusions. Ther Drug Monit 1995;17:471-8
   PubMed Web of Science ®Google Scholar
• Furman WL, Baker SD, Pratt CB, Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 1996;14:1504-11
   PubMed Web of Science ®Google Scholar
• Woo MH, Relling MV, Sonnichsen DS, Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin Cancer Res 1999;5:543-9
   PubMed Web of Science ®Google Scholar
• Pinguet F, Culine S, Bressolle F, A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies. Clin Cancer Res 2000;6:57-63
   PubMed Web of Science ®Google Scholar
• Eisenberger MA, Sinibaldi VJ, Reyno LM, Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 1995;13:2174-86
   PubMed Web of Science ®Google Scholar
• Falcone A, Antonuzzo A, Danesi R, Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer 1999;86:470-6
   PubMed Web of Science ®Google Scholar
• Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 2002;16:253-62
   PubMed Web of Science ®Google Scholar